PCIA
BBP icon

Prime Capital Investment Advisors’s Virtus Biotech ETF BBP Stock Holding History

Prime Capital Investment Advisors’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
16,847
-6,880
-29% -$566K 0.02% 427
2025
Q4 		$1.9M Buy
+23,727
New +$1.8M 0.02% 359

Other funds holding BBP

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prime Capital Investment Advisors's BBP Position: Q1 2026 in Review

Prime Capital Investment Advisors reduced its Virtus Biotech ETF (BBP) stake by 29% in Q1 2026, selling an estimated $566K and leaving 16,847 shares worth $1.4M. The position accounts for 0.02% of the portfolio, ranked #427.

Prime Capital Investment Advisors first reported a position in BBP in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.9M in Q4 2025. 26 funds tracked by Wall St. Rank hold BBP as of Q1 2026.

  • Prime Capital Investment Advisors held 16,847 shares of Virtus Biotech ETF worth $1.4M as of Q1 2026.
  • Prime Capital Investment Advisors sold 6,880 Virtus Biotech ETF shares in Q1 2026, an estimated $566K.
  • Virtus Biotech ETF made up 0.02% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #427 holding.
  • Prime Capital Investment Advisors first reported a position in Virtus Biotech ETF in Q4 2025 and has held it in 2 quarters since.
  • Prime Capital Investment Advisors's Virtus Biotech ETF position peaked at $1.9M in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.